Matthew Lincoln, DO
Guthrie Provider
- Gastroenterology and Hepatology
- Guthrie Corning Hospital
- Guthrie Robert Packer Hospital
- Gastrointestinal Endoscopy
- Inflammatory Bowel Disease
- Liver Disease
Appointments & Contact
Accepting New Patients
For New Patients
Locations
Education
- San Antonio Military Medical Center, Ft. Sam Houston, Texas (Internal Medicine)
- American College of Gastroenterology
- American Gastroenterological Association
- American Society for Gastrointestinal Endoscopy
- American College of Physicians
- American Board of Internal Medicine, Gastroenterology
- American Board of Internal Medicine, Internal Medicine
- University of New England College of Osteopathic Medicine, Biddeford, Maine
- San Antonio Military Medical Center, Ft. Sam Houston, Texas (Gastroenterology)
Clinical Trials
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn's Disease
- AbbVie M14-234, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
- ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI)
- Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
- M14-533, A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis
- M14-675, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis
- Protocol SMT19969/C005 (Ri-CoDIFy 2): A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium diffi
- RLM-MD-02, A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
- RLM-MD-04: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
Patient Comments